<DOC>
	<DOCNO>NCT00442260</DOCNO>
	<brief_summary>Dose Finding Efficacy Evaluation DOXIL ( Doxorubicin HCL Liposome Injection ) Combination Abraxane ( Abraxane ) Patients Metastatic Breast Cancer ( MBC ) [ Phase I II ]</brief_summary>
	<brief_title>Doxorubicin HCL Liposome Injection ( DOXIL ) Combination With Abraxane Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase I Objectives - To determine Maximum Tolerated Dose ( MTD ) combination ( DOXIL ) Abraxane patient Metastatic Breast Cancer ( MBC ) . - Determine dose-limiting toxicity ( DLT ) DOXIL Abraxane . Phase II Objectives Primary Objective - To determine response rate DOXIL Abraxane patient MBC . Secondary Objectives - To determine time disease progression patient MBC receive DOXIL Abraxane . - To assess tolerability regimen woman MBC ass toxicity profile</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Male female age 18 . ECOG performance status 02 . Patients biopsy proven radiologically confirm metastatic breast cancer . Chemotherapy na√Øve metastatic set one prior regimen metastatic breast cancer . Patients multiple nonchemotherapy agent metastatic breast cancer eligible i.e . hormonal therapy , Herceptin , Avastin etc . If receive taxane anthracyclines adjuvant metastatic setting , interval 12 month cumulative dose anthracycline take account ( adjuvant metastatic setting ) . Patients Her2/neu negative breast cancer . No significant comorbid condition determine investigator . Patients must normal cardiac function , evidence left ventricular ejection fraction ( LVEF ) within institutional normal limit . A MUGA scan echocardiogram ( test must use throughout study ) evaluate LVEF must do within 4 week ( 28 day ) . Normal laboratory value explain . No active malignancy past 5 year ( non melanomatous cutaneous cancer , cervical intraepithelial neoplasia , insitu cervical cancer ) . Ability understand willingness sign write informed consent document . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) great equal 20 mm conventional technique great equal 10 mm spiral CT scan . See section evaluation measurable disease . The protocol employ RECIST criterion . Negative serum urine pregnancy test screening patient childbearing potential Patients reproductive potential must use adequate contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , barrier device spermicide surgical sterilization ) treatment three month complete treatment . Pregnant breastfeeding . Patients CNS metastatic disease exclude diffuse involvement CSF spread metastasis amenable gamma knife surgery neurosurgical intervention ( Following neurosurgical removal solitary 3 metastasis follow gammaknife procedure 3 metastasis , patient become eligible ) . For patient stable CNS metastasis 12 month eligible study . Evidence significant comorbid condition end organ dysfunction . Patients Grade 3 4 neuropathy baseline evaluation cause also exclude . Patients permit receive radiation therapy ( palliative primary ) , study drug hold course radiation therapy hematopoietic recovery . The irradiated site use response Phase II setting . Prior anthracycline dose exceed 360 mg/m2 doxorubicin ( include Doxil ) 720 mg/m2 epirubicin make ineligible . History hypersensitivity reaction attribute conventional formulation doxorubicin HCL component DOXIL . Prior history severe reaction Taxol also make ineligible . Myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) Class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>advanced breast cancer</keyword>
</DOC>